Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00314275 · ClinicalTrials.gov registry record · NA
The ENDEAVOR Pharmacokinetic (PK) Registry: The Medtronic Endeavor Drug Eluting Coronary Stent System
A NA study, sponsored by Medtronic Vascular.
- Completed
- Registry status
- NA
- Development phase
- 43
- Enrollment target
NCT00314275 is a NA study that has completed, run by Medtronic Vascular. The registered enrollment target is 43 participants.
The verdict
NCT00314275, a NA study, has completed, sponsored by Medtronic Vascular.
- COMPLETED
- Registry status
- NA
- Development phase
- 43 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the pharmacokinetics (PK) and safety associated with ABT-578 administered using the Medtronic Endeavor Drug Eluting Coronary Stent system in the treatment of single de novo lesions in native coronary arteries between 2.5 - 3.5 mm in diameter.
Interventions
- DEVICE Endeavor
- DEVICE Coronary Artery Stenting
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2006-01 |
| Est. Completion | 2011-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00314275
The ClinicalTrials.gov registry entry for NCT00314275 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic Vascular, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Endeavor is the first listed.
NCT00314275 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00314275 about?
NCT00314275 is a clinical study titled "The ENDEAVOR Pharmacokinetic (PK) Registry: The Medtronic Endeavor Drug Eluting Coronary Stent System". The purpose of this study is to evaluate the pharmacokinetics (PK) and safety associated with ABT-578 administered using the Medtronic Endeavor Drug Eluting Coronary Stent system in the treatment of single de novo lesions in native coronary arteries between 2.5 - 3.5 mm in diameter.
What is the current status of trial NCT00314275?
This trial is currently completed. It is a NA study. The enrollment target is 43 participants. The study started on 2006-01. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00314275?
The interventions under investigation include: Endeavor (DEVICE), Coronary Artery Stenting (DEVICE).
Who is sponsoring clinical trial NCT00314275?
This trial is sponsored by Medtronic Vascular, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.